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Abstract
We previously observed that TRAIL induces acquired TRAIL resistance coinciding with increased
Akt phosphorylation brought about by the Src-PI3K-Akt signaling pathways and mediated by c-
Cbl. c-Cbl, a ubiquitously expressed cytoplasmic adaptor protein, is simultaneously involved in
the rapid degradation of TRAIL receptors and Akt phosphorylation during TRAIL treatment.
Here, we show that Akt phosphorylation is not exclusively responsible for acquired TRAIL
resistance. Akt catalytic activation is known to increase during metabolic oxidative stress, but we
show that TRAIL also dramatically induces the catalytic activation of Akt in TRAIL-sensitive
cells, but not in TRAIL-resistant cells. This suggests that Akt catalytic activation during TRAIL-
induced apoptosis is likely to play a compensatory role in the maintenance of cell homeostasis. In
addition, activated p38 and phosphorylated HSP27 were found to act as downstream effector
molecules of p38 during TRAIL treatment and were shown to be responsible for increased Akt
catalytic and invasive activities.
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Introduction
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potential anticancer
agent. However, many cancer cell types, particularly some highly malignant tumors, are
resistant to apoptosis induction by TRAIL. Furthermore, some cancer cells that were
originally sensitive to TRAIL-induced apoptosis can become resistant after repeated
exposure (acquired resistance) (1,2). Intrinsic resistance at the beginning of treatment can
occur at different points in the signaling pathways of TRAIL-induced apoptosis (2).
However, the mechanisms of acquired TRAIL resistance remain largely unknown for most
cancer cells. TRAIL is likely to have other functions in addition to the induction of cell
death. For example, it is known to stimulate the anti-apoptotic phosphoinositide-3 kinase
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(PI3K)/Akt pathway in endothelial cells (3) and fibroblasts (4) and to induce PI3K/Akt and
nuclear factor-κB (NF-κB) activation in Jurkat T leukemia cells (5). These findings imply
that TRAIL can function as a cytokine of either cell death or cell survival depending on
certain circumstances such as cellular context.
Trauzold et al (6) have reported that TRAIL promotes metastasis of human pancreatic ductal
adenocarcinoma, demonstrating for the first time that TRAIL treatment strongly increases
distant metastasis of pancreatic tumors in vivo. However, the molecular mechanism of
TRAIL-induced tumor invasion and metastasis remains poorly understood. We previously
noted that TRAIL can induce apoptosis of cancer cells when used as a chemotherapeutic
drug. At the same time, TRAIL-resistant cells may develop the potential for progression to
invasive or metastatic cancer by increasing pAkt and Bcl-xL expressions (7), which
eventually lead to the degradation of the extracellular matrix, a typical sign of tumor
invasion and metastasis (8). Human collagenase-3 (matrix metalloproteinase-13, MMP-13)
belongs to the subfamily of interstitial collagenases that cleave stromal collagens types I and
III (8). MMP-13 is a recently identified member of the MMP family that was originally
isolated from breast carcinoma (9), and its wide substrate specificity also makes it a potent
proteolytic tool for invading tumor cells (10–12). Monocyte chemotactic protein-1 (MCP-1)
is a member of the chemokine superfamily that plays a key role in the recruitment and
activation of monocytes during inflammation and angiogenesis (13). Lu et al (14) have
demonstrated that MCP-1 also promotes prostate cancer cell proliferation and invasion in
vitro by correlating higher MCP-1 patient serum levels with various advanced stage cancers.
Previously, we observed that TRAIL increases Akt phosphorylation and induces the Akt
signaling pathway through the involvements of Rous sarcoma oncogene cellular homolog
(src), PI3K and pAkt via Casitas B-lineage lymphoma (c-Cbl) (15). However, we also found
that the catalytic activity of Akt other than Akt phosphorylation was increased by the
dissociation of its negative regulator JNK-interacting protein (JIP1), as a negative feedback
against metabolic oxidative stress (16). We thus hypothesized that the downstream signaling
pathways of TRAIL and metabolic oxidative stress are somewhat similar in that they both
induce c-Jun NH2-terminal kinase (JNK)/p38 activation (16,17). In general, different
mitogen-activated protein kinases (MAPKs) are members of separate modules and are
regulated by distinct extracellular stimuli. For example, extracellular signal-regulated
kinases (ERKs) are activated by receptor tyrosine kinases and play a central role in
mitogenic signaling (18,19), while JNK and p38-type MAPKs are activated predominantly
by stress stimuli and pathogenic insults (18). However, unlike their known typical patterns
to corresponding stimuli, there are also many reports that each MAPK has pro- or
antiapoptotic functions depending on cell type, nature of the death stimulus, duration of
activation and the activities of other signaling pathways (20–23).
Activated p38 phosphorylates mitogen-activated protein kinase-activated protein kinase 2
(MAPKAPK2), which in turn phosphorylates HSP27 (24,25). The mammalian small stress
protein HSP27 is a phosphoprotein that forms large oligomers (up to 800 kD) with strong
antiapoptotic properties that acts as a molecular chaperone to protect cells from heat shock
and oxidative stress (26). Small HSPs (sHSPs; monomers of 15–42 kD) act as molecular
chaperones to prevent unfolded proteins from irreversible aggregation, cooperating with
other factors, e.g., HSP70 and ATP, to facilitate productive refolding (27). In addition,
mammalian sHSPs are rapidly phosphorylated in response to various extracellular stresses,
including oxidative stress, by MAPK-activated proteins kinase 2, a substrate of p38 (25,28).
Increased phosphorylation of mammalian sHSPs leads to changes in oligomeric
organization. For instance, induction of HSP27 phosphorylation leads to reduction of the
oligomeric size to ~70–250 kD and is accompanied by the down-regulations of both
chaperone action and resistance against oxidative stress (27). However, more recently, Xu et
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al (29) showed that HSP phosphorylation induced by p38 MAP kinase was necessary for the
transforming growth factor-β (TGF-β)-mediated increase in MMP-2 and cell invasion in
human prostate cancer. Here, we investigated the possibility of Akt catalytic activation in
TRAIL-induced signaling pathways. We found that TRAIL-induced p38 activation and
subsequent HSP27 phosphorylation were responsible for increased Akt catalytic and
invasive activities.
Materials and methods
Cell culture
A human prostate adenocarcinoma cell line, DU-145, and SK-OV-3, a human ovarian
carcinoma cell line, were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with
10% fetal bovine serum (FBS) (HyClone, Logan, UT, USA) and 26 mM sodium
bicarbonate. A human prostate adenocarcinoma cell line, LNCaP, was cultured in
RPMI-1640 with 10% FBS and 26 mM sodium bicarbonate. The cells were maintained in a
37°C humidified atmosphere containing 5% CO2 and air.
Reagents and antibodies
The p38 inhibitor SB203580 was purchased from Calbiochem (San Diego, CA, USA). Anti-
Akt, anti-Bad, anti-phospho-Bad, anti-GSK-3, anti-phospho-GSK-3, anti-p38, anti-phospho-
p38, anti-phosphoS473-Akt and anti-Bcl-xL antibodies were purchased from Cell Signaling
(Beverly, MA, USA). Anti-MMP13 antibody and protein G were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Anti-actin antibody was purchased from ICN
(Costa Mesa, CA, USA). Anti-HSP27 and anti-phospho-HSP27 (Ser 78) antibodies were
purchased from Assay Designs (Ann Arbor, MI, USA). Monoclonal anti-PARP antibody
was purchased from Biomol International, L.P. (Plymouth Meeting, PA, USA). Other
chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Protein extracts and polyacrylamide gel electrophoresis
Cells were lysed with 1× Laemmli lysis buffer (2% sodium dodecyl sulfate, 10% glycerol,
0.002% bromophenol blue and 62.5 mM Tris, pH 6.8) and boiled for 10 min. Protein content
was measured with BCA Protein Assay Reagent (Pierce, Rockford, IL, USA). The samples
were diluted with 1× lysis buffer and β-mercaptoethanol (final concentration 350 mM), and
then equal amounts of protein were loaded onto 10 or 15% sodium dodecyl sulfate (SDS)-
polyacrylamide gels. SDS-PAGE analysis was performed according to the method of
Laemmli using a Hoefer gel apparatus.
Immunoblot analysis
Proteins were separated by SDS-PAGE and were electrophoretically transferred to
nitrocellulose membranes. Each nitrocellulose membrane was blocked with 5% non-fat dry
milk in PBS-Tween-20 (0.1%, v/v) at 4°C overnight. The membrane was then incubated
with primary antibody (diluted according to the manufacturer’s instructions) for 2 h.
Horseradish peroxidase conjugated anti-rabbit or anti-mouse IgG was used as the secondary
antibody. Immunoreactive proteins were visualized by chemiluminescence (ECL,
Amersham, Arlington Heights, IL, USA).
Immune complex kinase assay
For the immune complex kinase assay, DU-145, LNCaP, or SK-OV-3 cells were lysed after
TRAIL treatment in a buffer solution containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5
mM EGTA, 10 mM NaF, 1% Triton X-100, 0.5% deoxycholate, 2 mM DTT, 1 mM sodium
orthovanadate, 1 mM PMSF, and protein inhibitor cocktail solution (Sigma-Aldrich). Cell
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extracts were clarified by centrifugation, and the supernatants were immunoprecipitated with
mouse anti-Akt antibody and protein G agarose (Santa Cruz Biotechnology, Inc.). The beads
were washed twice with a solution containing 150 mM NaCl, 20 mM Tris-HCl, pH 7.5, 5
mM EGTA, 2 mM DTT, 1 mM sodium orthovanadate, 1 mM PMSF, and protein inhibitor
cocktail solution, washed once more with the kinase buffer solution, and subjected to kinase
assays. To examine the catalytic activity of Akt, glutathione-S transferase (GST)-tagged Bad
fusion protein (Santa Cruz Biotechnology, Inc.) and glycogen synthase kinase 3 (GSK-3)
fusion protein (Cell Signaling) were used as substrates. Bad (1 μg) or GSK-3 was incubated
with immunoprecipitated Akt in kinase buffer containing 20 mM Tris-HCl, pH 7.5, 20 mM
MgCl2, 1 mM sodium orthovanadate, 2 mM DTT, and 20 μM ATP at 30°C for 1 h. The
reaction was stopped by adding 2× Laemmli buffer. Phosphorylated proteins were resolved
using SDS-PAGE and analyzed using immunoblotting with anti-phospho-Bad (Ser-136) or
anti-phospho-GSK-3α/β antibodies (Cell Signaling).
Invasion assay
DU-145 cells were cultured in invasion chambers (Millipore, ECM551) after TRAIL
treatment (200 ng/ml for 4 h) with or without SB203580 (20 μM) pretreatment. DU-145
cells with acquired TRAIL resistance were cultured in invasion chambers with a thin layer
of ECMatrix in serum-free media for 48 h. Invasive cells that migrated through the ECM
layer and adhered to the bottom of the polycarbonate membrane in 10% serum-containing
media were stained.
MCP-1 ELISA assay
MCP-1 was quantified using a commercially available sandwich-type ELISA (R&D
Systems). DU-145 cells pretreated with or without p38 inhibitor (SB203580 at 20 μM for 1
h) were then treated with TRAIL (200 ng/ml for 4 h). Cells were subsequently incubated
with or without SB203580 for two days. Supernatants were harvested from attached DU-145
cells two days after TRAIL treatment and were incubated in wells pre-coated with a
monoclonal antibody specific for MCP-1. After washing away any unbound substances, an
enzyme-linked polyclonal antibody specific for MCP-1 was added to the wells. After
washing, a substrate solution for color development was finally added to the wells, and the
intensity of the color was measured for MCP-1 quantification.
Results
TRAIL induced Akt catalytic activity during apoptosis
We previously found that TRAIL-induced Akt phosphorylation plays an important role in
the development of acquired TRAIL resistance (7), suggesting that TRAIL, in addition to
being a death-inducing ligand, may also be involved in the survival of cancer cells (15).
Here, we observed an increase in Akt phosphorylation in the attached cells after TRAIL
treatment (Fig. 1A). However, Akt phosphorylation was harder to detect for TRAIL
treatment at a concentration of 200 ng/ml (Fig. 1B) compared to those at lower
concentrations (15). We questioned whether TRAIL was contributing to Akt activation only
by increasing Akt phosphorylation or whether it was activating Akt in other ways to affect
cell survival and acquired TRAIL resistance. We therefore examined whether Akt was being
catalytically activated during TRAIL treatment as it was being catalytically activated under
conditions of glucose deprivation (16). Surprisingly, Akt catalytic activity significantly
increased during TRAIL treatment when Bad protein was used as an in vitro Akt substrate,
but did not increase when GSK protein was used as a substrate (Fig. 2A). The increase in
Akt catalytic activity began after 30 min of treatment and was sustained for >4 h (Fig. 2B).
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TRAIL-induced Akt catalytic activation is dependent on the activated caspase 8-dependent
phospho-p38/phospho-HSP27 signaling pathways
Next, we investigated the reason for the increased Akt catalytic activity during TRAIL
treatment. We hypothesized that the catalytic activation of Akt was a compensatory
mechanism for protection of the cell from TRAIL-induced apoptosis. We therefore
investigated whether catalytic activation of Akt also occurred in TRAIL-resistant cell lines
such as LNCaP (30) or SK-OV-3 (31), which have higher levels of Akt phosphorylation and
show resistance to TRAIL-induced apoptosis (Fig. 3A). In contrast to the TRAIL-sensitive
cell line DU-145, TRAIL-induced Akt catalytic activity did not increase in LNCaP or SK-
OV-3 cells (Fig. 3B). Based on this result, we hypothesized that TRAIL-induced Akt
catalytic activation was preceded by caspase activation. This prompted us to re-examine
TRAIL-induced Akt catalytic activation in the presence of caspase 8 inhibitor. As expected,
TRAIL-induced Akt catalytic activation was also repressed by the caspase 8 inhibitor (Fig.
3C).
We further confirmed that TRAIL-induced Akt catalytic activation rather than Akt
phosphorylation was strongly related to p38 phosphorylation (activation) (Fig. 4A), and that
other MAPKs such as JNK or ERK were not responsible for the increase in Akt catalytic
activity (data not shown). For this experiment, we examined the phosphorylation of HSP27
as a positive downstream effector molecule of p38 (29). We found complete repression of
HSP27 phosphorylation in the presence of SB203580. Since SB203580 acts as a p38
catalytic inhibitor via competitive binding in the ATP pocket, phosphorylation of p38 in the
presence of inhibitor did not change substantially.
Phosphorylation of HSP27 is necessary for TRAIL-induced Akt catalytic activation
A remaining question was the biological role of phosphorylated HSP27 during TRAIL
treatment. We observed that Akt interacted with HSP27, and that phosphorylated HSP27
showed increased interaction with Akt during TRAIL treatment (Fig. 4B). To elucidate the
effect of phosphorylated HSP27 on Akt catalytic activity, Akt catalytic activity was assayed
after overexpression of wild-type HSP27 and a non-phosphorylatable 3A-HSP27 mutant,
kindly provided by Dr Michael J. Welsh (University of Michigan). TRAIL-induced Akt
catalytic activity was significantly repressed in cells that overexpressed the non-
phosphorylatable 3A-HSP27 mutant (Fig. 4C), suggesting that phosphorylated HSP27 is
required for TRAIL-induced Akt catalytic activation.
TRAIL-induced invasive activity is dependent on the TRAIL-p38 signaling pathway
Varfolomeev et al (32) suggested that TRAIL-dependent activation of the kinase pathway is
associated with increased production of the chemokine MCP-1 that plays a role in prostate
cancer invasion and metastasis (14,32). Based on our finding of a TRAIL-dependent
increase in Akt catalytic activity that was mediated by phosphorylated HSP27 and p38
activations (Fig. 4A and C), we therefore decided to use p38 inhibitor (SB203580) to
investigate the involvement of p38 in cell invasion activity, both during and after TRAIL
treatment. Overexpression of MMP13 or MCP-1 was repressed in the presence of p38
inhibitor before and after acquisition of TRAIL resistance (Fig. 5A and B), suggesting that
p38 activation was transmitted to its potential downstream signals such as Akt, MMP13 or
MCP-1 to produce acquired TRAIL resistance and TRAIL-induced invasion. We used
ECMatrix to confirm that the acquired cells had increased invasive potential, and that p38
activation was imperative for this TRAIL-induced invasive activity (Fig. 5C). DU-145 cells
with acquired TRAIL resistance that were cultured in invasion chambers with a thin layer of
ECMatrix displayed much higher invasive activity than did p38 inhibitor-pretreated DU-145
cells with acquired TRAIL resistance.
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Working hypothesis of anti-apoptotic role of p38 induced by TRAIL
Collectively, our previous and current experimental data suggest that TRAIL induces both
anti-apoptotic and apoptotic signals in parallel. When TRAIL binds to its receptors, it
activates caspase 8 through adaptors such as FADD and eventually leads to apoptosis. At the
same time or subsequently, TRAIL also induces Akt phosphorylation through Src/c-Cbl and/
or Akt catalytic activation through p38 activation/phosho-HSP27, respectively, resulting in
survival or invasive activation (Fig. 6).
Discussion
We have previously investigated the side-effects of acquired TRAIL resistance during
TRAIL-induced apoptosis. These studies showed that phosphorylation of Akt and rapid
degradation of TRAIL receptors (DR4/5) during TRAIL treatment were the underlying
mechanisms of acquired TRAIL-resistance (7,15,33). However, as reported elsewhere (17),
MAPKs are also activated during TRAIL-induced apoptosis, and their activation is caspase
8-dependent. Here we reconciled these findings by investigating the biological function of
p38 activation induced by TRAIL treatment in the prostate cancer cell line, DU-145.
As shown in our previous study (16), phosphorylation of Akt does not always reflect its own
catalytic activity. Our current study further reinforced the hypothesis that Akt activity is
mainly derived from Akt catalytic activity rather than Akt phosphorylation (Figs. 1C and
2B). In addition, the increase in TRAIL-induced Akt catalytic activity in TRAIL-sensitive
cells, but not in TRAIL-resistant cells, implied that cancer cells possess a mechanism to
protect themselves from cell death in a negative feedback manner. This finding suggested
that TRAIL-mediated activation of caspase 8 and its downstream signals such as p38 could
play an essential role in promoting Akt catalytic activation. As noted by Fan and Bergmann
(34), maintenance of cell homeostasis is a crucial compensatory mechanism for the survival
of multicellular organisms against cell death.
The serine/threonine kinase Akt regulates multiple biological processes, including survival,
proliferation, cell growth and glycogen metabolism (35–37). A number of pro-apoptotic
proteins have been identified as direct Akt substrates, including Forkhead transcription
factors, caspase 9 and Bad (38–43). Phosphorylation by Akt suppresses the pro-apoptotic
functions of these molecules. How Akt can mediate upstream signaling to its appropriate
downstream signals without impairing other cellular functions in the presence of so many
substrates with different cellular functions remains an intriguing question. Fig. 2A displays
one possible answer to this question. TRAIL induced Akt activation only when Bad protein
was used as a substrate and not when GSK-3 protein was used as a substrate. These results
provide a possible mechanism by which a single Akt molecule can finely regulate various
signals depending on the nature of the stimulation. The Akt binding pocket for Bad, but not
that for GSK-3, may be specifically affected by TRAIL treatment in a positive manner.
The main biological function of phosphorylated HSP27 during TRAIL treatment was Akt
activation, which in turn resulted in increased invasive activities of cancer cells. However,
as previously reported, phosphorylated HSP27 can induce down-regulation of chaperone
action and resistance against oxidative stress. A plausible explanation for this discrepancy
can be found in several studies which have shown that MAPKs such as JNK, p38 or ERK1/2
may play dual roles depending on the duration and magnitude of their action (21,44). For
example, p38 has various diverse effects depending on stimuli, cellular context, or even cell
type (45,46). In other words, in certain conditions, p38 functions as a suppressor of cell
proliferation and tumorigenesis (47), while in other cases, p38 regulates invasion and growth
of head and neck squamous carcinoma cells (48) or protects against TNF-α-provoked
apoptosis in prostate cancer cells or murine fibroblasts (49,50). Phosphorylated HSP27 may
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also play different roles depending on the duration and magnitude of its action, a possibility
that is currently being investigated.
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Figure 1.
Akt phosphorylation during the development of acquired TRAIL resistance and during
TRAIL treatment. (A) DU-145 cells were treated with TRAIL (200 ng/ml) for 4 h. Detached
cells were then removed by washing with PBS, followed by the addition of fresh media to
the remaining attached cells, which were then incubated for the indicated times (0, 1, 2
days). Cells were lysed, and lysates were analyzed for phosphorylated Akt, and Akt. Actin
was used to confirm equal amount of proteins loaded into each lane. Lane 1, control; lane 2,
attached cells after 0 day of TRAIL; lane 3, attached cells after 1 day of TRAIL; lane 4,
attached cells after 2 days of TRAIL (B) DU-145 cells were treated with 200 ng/ml TRAIL
for various times (0–4 h). Cells were lysed, and lysates were analyzed for the presence of
PARP, phosphorylated Akt and Akt. Actin was used to confirm that equal amounts of
protein were loaded into each lane.
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Figure 2.
Akt catalytic activity during TRAIL treatment. (A) DU-145 cells were treated with 200 ng/
ml TRAIL for 4 h. Cells were lysed, and lysates were immunoprecipitated (IP) with mouse
anti-Akt antibody. Catalytic activity of immunoprecipitated Akt after TRAIL treatment was
estimated for GST-Bad or GST-GSK-3 fusion protein substrates. GST-Bad, phosphorylated
GST-Bad, GST-GSK-3 and phosphorylated GST-GSK-3 were detected with anti-Bad, anti-
phospho-Ser-136-Bad, anti-GSK-3α, or anti-phospho-GSK-3α/β antibodies, respectively.
Immunoprecipitated Akt was detected with rabbit anti-Akt antibody. (B) DU-145 cells were
lysed after exposure to TRAIL (200 ng/ml) for various times, and lysates were
immunoprecipitated with anti-Akt antibody. Akt catalytic activity was examined in vitro
using GST-Bad protein as a substrate. GST-Bad and phosphorylated GST-Bad were
detected with anti-Bad and anti-phospho-Ser-136-Bad antibodies, respectively.
Immunoprecipitated Akt was detected with rabbit anti-Akt antibody.
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Figure 3.
Akt catalytic activity dependence on TRAIL-sensitivity and the caspase 8-dependent
signaling pathway. (A) Akt phosphorylation was estimated in TRAIL-sensitive DU-145
cells and TRAIL-resistant LNCaP and SK-OV-3 cells. Each cell line was treated with 200
ng/ml TRAIL for 4 h, and lysates were immunoblotted with anti-phospho Akt antibody. (B)
DU-145, LNCap and SK-OV3 cells were lysed, and the lysates were immunoprecipitated
with mouse anti-Akt antibody. Akt catalytic activity was examined in vitro using GST-Bad
protein as a substrate. GST-Bad and phosphorylated GST-Bad were detected with anti-Bad
and anti-phospho-Ser-136-Bad antibodies, respectively. Immunoprecipitated Akt was
detected with rabbit anti-Akt antibody (upper panel). Cell lysates were immunoblotted with
anti-PARP or anti-actin antibody, respectively (lower panel). (C) DU-145 cells were
pretreated with caspase 8 inhibitor (Z-IETD-FMK 20 μM, 30 min), followed by TRAIL
treatment (200 ng/ml) for 2 h, and were lysed, and the lysates were immunoprecipitated with
mouse anti-Akt antibody. Akt catalytic activity was examined in vitro using GST-Bad
protein as a substrate. GST-Bad and phosphorylated GST-Bad were detected with anti-Bad
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and anti-phospho-Ser-136-Bad antibodies, respectively. Immunoprecipitated Akt was
detected with rabbit anti-Akt antibody (upper panel). Cell lysates were immunoblotted with
anti-PARP, anti-caspase 8 or anti-actin antibody, respectively (lower panel).
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Figure 4.
Akt catalytic activity dependence on the phospho-p38/phospho-HSP27 signaling pathway.
(A) DU-145 cells pretreated with or without p38 inhibitor were lysed after TRAIL
treatment, and the lysates were immunoprecipitated with anti-Akt antibody. Akt catalytic
activity was examined in vitro using GST-Bad protein as a substrate. GST-Bad and
phosphorylated GST-Bad were detected with anti-Bad and anti-phospho-Ser-136-Bad
antibodies, respectively. Immunoprecipitated Akt was detected with rabbit anti-Akt antibody
(upper panel). Cell lysates were immunoblotted with anti-phospho-p38, anti-p38, anti-
phospho-HSP27, anti-HSP27, anti-phospho-Akt or anti-actin antibody, respectively (lower
panel). Phospho-HSP27 served as a positive control for p38 inhibitor treatment. (B) Cell
lysates were immunoprecipitated with anti-Akt antibody. Phosphorylated HSP27, HSP27, or
Akt was detected with anti-phospho-HSP27, anti-HSP27, or anti-Akt antibody, respectively
(upper panel). Cell lysates were immunoblotted with anti-phospho-p38, anti-p38, anti-
phospho-HSP27, or anti-HSP27, respectively (lower panel). (C) Cells were transfected with
pcDNA3.1+/HSP27 (wild-type) or mutant-type (3A HSP27). After a 48-h incubation, cells
were treated with TRAIL (200 ng/ml) for 2 h and then immunoprecipitated with anti-Akt
antibody. Akt catalytic activity was examined in vitro using GST-Bad protein as a substrate.
GST-Bad and phosphorylated GST-Bad were detected with anti-Bad and anti-phospho-
Ser-136-Bad antibodies, respectively. Immunoprecipitated Akt was detected with rabbit
anti-Akt antibody (upper panel). Cell lysates were immunoblotted with anti-phospho-
HSP27, anti-HSP27, anti-PARP, or anti-actin antibodies (lower panel). wt, wild-type; mt,
mutant-type
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Figure 5.
Biological role of p38 during TRAIL-induced invasive activity. (A) The level of MMP13
was examined using the p38 inhibitor SB203580 (20 μM). Following 1 h of pretreatment
with SB203580, cells were treated with TRAIL (200 ng/ml) for 4 h. After TRAIL treatment,
the remaining cells were incubated with SB203580 for two days. (Lane 1, control; lane 2,
attached cells after two days of TRAIL treatment; lane 3, SB203580; lane 4, SB203580
pretreated with TRAIL treatment followed by SB203580 for two days.) (B) Following 1 h
pretreatment with SB203580, cells were treated with TRAIL (200 ng/ml) for 4 h. After
TRAIL treatment, the remaining cells were incubated with SB203580 for two days. The
supernatants from attached cells were harvested two days after TRAIL treatment, and the
levels of MCP-1 were quantified using a commercially available sandwich-type ELISA
(R&D Systems). (C) DU-145 cells were cultured in invasion chambers after TRAIL
treatment (200 ng/ml for 4 h) with or without SB203580 (20 μM) pretreatment. The
remaining DU-145 cells in chambers with a thin layer of ECMatrix were cultured in serum-
free media with or without SB203580 for two days. Invasive cells that migrated through the
ECM layer and adhered to the bottom of the polycarbonate membrane in 10% serum-
containing media were stained.
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Figure 6.
Schematic diagram of TRAIL-induced apoptosis and anti-apoptosis signaling pathways.
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